Supernus Announces Fourth Quarter and Full Year 2019 Financial Results Read more about Supernus Announces Fourth Quarter and Full Year 2019 Financial Results
Supernus to Host Fourth Quarter and Full Year 2019 Results Earnings Conference Call Read more about Supernus to Host Fourth Quarter and Full Year 2019 Results Earnings Conference Call
Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD Read more about Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD
Supernus to Present at the 2020 J.P. Morgan Healthcare Conference Read more about Supernus to Present at the 2020 J.P. Morgan Healthcare Conference
Supernus Provides Update on Results from Phase III Study (P301) of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients Read more about Supernus Provides Update on Results from Phase III Study (P301) of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients
Supernus to Present at Two November Healthcare Conferences Read more about Supernus to Present at Two November Healthcare Conferences
Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD Read more about Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD
Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients Read more about Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients
Supernus to Host Third Quarter 2019 Earnings Conference Call Read more about Supernus to Host Third Quarter 2019 Earnings Conference Call
Supernus to Present at the 2019 Cantor Global Healthcare Conference Read more about Supernus to Present at the 2019 Cantor Global Healthcare Conference